Dublin, Aug. 07, 2018 (GLOBE NEWSWIRE) -- The "Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

This report gives comprehensive insights on the various drugs being developed for the treatment of NASH.

The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical).

The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs.

The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

Some of the key sections covered in the report are given below:

  • Epidemiology
    • In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.
    • Global & US prevalence rates.
  • Hot Targets, Mechanisms & Therapies
    • In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis).
  • Pipeline Analysis
    • Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development).
    • Pipeline analysis by modalities
  • Monoclonal Antibodies pipeline analysis
  • RNA-therapeutics pipeline analysis
  • Recombinant protein pipeline analysis
    • Pipeline analysis by leading players & Target analysis
    • Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic and Metabolic)

Key Topics Covered

1. Report Description

  • Causes & Symptoms
  • Diagnosis
  • Unmet Needs
  • Current Therapies

2. Hot Targets, Mechanisms & Therapies

  • Novel Disease Mechanisms & Therapies
  • Leading Targets Of NASH
  • Novel Targets Of NASH
  • Nash Biomarkers
  • Genes Involved In NASH

3. Market Data

  • Forecasting Model
  • Market Dynamics
  • Market Sizing And Peak Sales
  • NASH Deals
  • Funding Scenario

4. Pipeline Analysis

  • Development Stage
  • Leading Players
  • Molecule Type
  • Target Analysis
  • Clinical Update On Phase 3 Molecules
  • Innovative Approaches

5. Small Molecules

  • Pipeline
  • Competitive Landscape

6. Large Molecules

  • Antibodies
    • Pipeline
    • Competitive Analysis
  • Recombinant Proteins
    • Pipeline
    • Competitive Analysis
  • RNA-Based Therapy
  • Pipeline
  • Competitve Landscape
  • Pipeline

8. Other Molecules

  • Pipeline

9. NASH Drug Analysis Based On Mechanism (Clinical) 10. Major Players

  • Company Profiles
    • Overview
    • Pipeline
    • Deals

Companies Featured

  • Albireo Pharma
  • Allergan Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cerenis Therapeutics
  • Connexios Life Systems
  • Enanta Pharmaceuticals
  • GENFIT
  • Gilead Sciences Inc
  • NGM Biopharmaceuticals
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Promethera Biosciences
  • Prometic Lifesciences
  • Taiwanj Pharmaceuticals
  • Terns Pharmaceuticals
  • VBL Therapeutics
  • Viking Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/j...teato?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Liver and Kidney Disorders Drugs